Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug?
Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex ...
BioSpace2d
Cystic Fibrosis Biotech Sionna Announces $150M IPO
The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...
Vertex Pharma Just Scored a Major FDA Approval. Is the Stock a No-Brainer Buy Now?
Vertex Pharmaceuticals (NASDAQ: VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) ...
Vertex Pharmaceuticals price target raised to $540 from $522 at BofA
BofA analyst Tazeen Ahmad raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $540 from $522 and keeps a Buy rating on the ...
Is Vertex Pharmaceuticals Stock a Buy in 2025?
The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...
3 Magnificent Stocks to Buy and Hold Forever
Some you might hold only temporarily, while others you own for decades. David Jagielski (Eli Lilly): A forever stock you can ...
What's Happening With VRTX Stock?
With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...
Yahoo Finance2d
Vertex Pharmaceuticals Incorporated (VRTX)
Vertex Pharmaceuticals (VRTX) stock is rising after receiving approval by the Food and Drug Administration (FDA) over its new non-opioid pain management drug, Journavx. Lastly, oil giants Exxon ...
Investing5d
Vertex Pharmaceuticals' SWOT analysis: cystic fibrosis leader faces pipeline challenges
Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...